Jort Vellinga

2.6k citations

25 papers · 813 indexed · h-index 17

Co-authors: Rob C. Hoeben Martijn J. W. E. Rabelink Taco G. Uil Diana J.M. van den Wollenberg Jerome Custers Roland Zahn Jeroen de Vrij Steve J. Cramer
Topics: Virus-based gene therapy research (21 papers)Viral Infectious Diseases and Gene Expression in Insects (10 papers)CAR-T cell therapy research (8 papers)
Cited by: Infectious Diseases Genetics Oncology
Journals: Nucleic Acids Research PLoS ONE Journal of Virology
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Jort Vellinga

25 papers receiving 785 citations

Peers

Countries citing papers authored by Jort Vellinga

Since Specialization

Citations

This map shows the geographic impact of Jort Vellinga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jort Vellinga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jort Vellinga more than expected).

Fields of papers citing papers by Jort Vellinga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jort Vellinga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jort Vellinga. The network helps show where Jort Vellinga may publish in the future.

Co-authorship network of co-authors of Jort Vellinga

This figure shows the co-authorship network connecting the top 25 collaborators of Jort Vellinga. A scholar is included among the top collaborators of Jort Vellinga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jort Vellinga. Jort Vellinga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine 2023 ·Journal of Thrombosis and Haemostasis ·Marijn van der Neut Kolfschoten,(unknown),Clara Pérez‐Peinado,(unknown),(unknown),(unknown),(unknown),(unknown),Daniëlle van Manen,Jort Vellinga,Jerome Custers,Rinke Bos	3
2	Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses 2018 ·Vaccine ·Marija Vujadinovic,Selina Khan,Koen Oosterhuis,Taco G. Uil,Kerstin Wunderlich,(unknown),(unknown),Annemiek Verwilligen,(unknown),Jan Serroyen,Hanneke Schuitemaker,Roland Zahn,Gert C. Scheper,Jerome Custers,Jort Vellinga	18
3	Progress in Adenoviral Capsid-Display Vaccines 2018 ·Biomedicines ·Marija Vujadinovic,Jort Vellinga	19
4	Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform 2017 ·PLoS ONE ·(unknown),Marija Vujadinovic,(unknown),(unknown),(unknown),Jan Serroyen,Harmjan Kuipers,Hanneke Schuitemaker,Roland Zahn,Jerome Custers,Jort Vellinga	13
5	Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8⁺ T cell responses against HPV16 oncoproteins 2017 ·International Journal of Cancer ·Nicolas Çuburu,Selina Khan,Cynthia D. Thompson,Rina Kim,Jort Vellinga,Roland Zahn,Douglas R. Lowy,Gert C. Scheper,John T. Schiller	38
6	Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response 2017 ·Human Gene Therapy ·Marija Vujadinovic,Kerstin Wunderlich,Benoît Callendret,(unknown),Mark Vermeulen,(unknown),(unknown),(unknown),(unknown),Karin Boer,(unknown),Jan Serroyen,Maria Grazia Pau,Hanneke Schuitemaker,Roland Zahn,Jerome Custers,Jort Vellinga	1
7	Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats 2015 ·Vaccine ·Myra N. Widjojoatmodjo,Lies Bogaert,Bob Meek,Roland Zahn,Jort Vellinga,Jerome Custers,Jan Serroyen,Katarina Radošević,Hanneke Schuitemaker	46
8	Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment 2014 ·Human Gene Therapy ·Jort Vellinga,(unknown),Agnieszka Lipiec,Dragomira Majhen,Angelique A. C. Lemckert,(unknown),P. M. Ives,(unknown),Jerome Custers,Menzo Havenga	63
9	Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling 2012 ·Molecular Immunology ·Jens Pahl,(unknown),Kitty M.C. Kwappenberg,Jort Vellinga,Arjan C. Lankester,Maarten J. D. van Tol,Marco W. Schilham	16
10	Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species 2012 ·PLoS ONE ·Roland Zahn,(unknown),(unknown),(unknown),(unknown),(unknown),Mo Weijtens,Maria Grazia Pau,Katarina Radošević,Gerrit Jan Weverling,Jerome Custers,Jort Vellinga,Hanneke Schuitemaker,Jaap Goudsmit,Ariane Rodrı́guez	42
11	A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction 2011 ·Gene Therapy ·Jeroen de Vrij,(unknown),S K van den Hengel,Maria K. Magnusson,Taco G. Uil,Steve J. Cramer,Jort Vellinga,Carla S. Veríssimo,Leif Lindholm,Danijela Koppers‐Lalic,Rob C. Hoeben	8
12	Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge 2011 ·Journal of Virology ·Thomas W. Geisbert,Michael Bailey,Lisa E. Hensley,Clement Asiedu,Joan B. Geisbert,Daphne A. Stanley,Anna N. Honko,Joshua C. Johnson,Sabué Mulangu,Maria Grazia Pau,Jerome Custers,Jort Vellinga,Jenny Hendriks,Peter B. Jahrling,Mario Roederer,Jaap Goudsmit,Richard A. Koup,Nancy J. Sullivan	147
13	Directed adenovirus evolution using engineered mutator viral polymerases 2010 ·Nucleic Acids Research ·Taco G. Uil,Jort Vellinga,Jeroen de Vrij,S K van den Hengel,Martijn J. W. E. Rabelink,Steve J. Cramer,Julia J.M. Eekels,Yavuz Ariyürek,Michiel van Galen,Rob C. Hoeben	26
14	A lentiviral vector‐based adenovirus fiber‐pseudotyping approach for expedited functional assessment of candidate retargeted fibers 2009 ·The Journal of Gene Medicine ·Taco G. Uil,Jeroen de Vrij,Jort Vellinga,Martijn J. W. E. Rabelink,Steve J. Cramer,(unknown),(unknown),Maria K. Magnusson,Leif Lindholm,Pierre Boulanger,Rob C. Hoeben	9
15	Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX 2008 ·Gene Therapy ·Jeroen de Vrij,Taco G. Uil,S K van den Hengel,Steve J. Cramer,Danijela Koppers‐Lalic,Marieke C. Verweij,Emmanuel J. H. J. Wiertz,Jort Vellinga,Ralph A. Willemsen,Rob C. Hoeben	19
16	Replacement of Native Adenovirus Receptor-Binding Sites with a New Attachment Moiety Diminishes Hepatic Tropism and Enhances Bioavailability in Mice 2008 ·Human Gene Therapy ·Frederik H.E. Schagen,Harm C.A. Graat,Jan E. Carette,Jort Vellinga,(unknown),Rob C. Hoeben,Terence S. Dermody,Victor W. van Beusechem	7
17	Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid 2007 ·Gene Therapy ·Jort Vellinga,Jeroen de Vrij,(unknown),Taco G. Uil,Pierre Martineau,Leif Lindholm,Rob C. Hoeben	34
18	A system for efficient generation of adenovirus protein IX‐producing helper cell lines 2005 ·The Journal of Gene Medicine ·Jort Vellinga,Taco G. Uil,Jeroen de Vrij,Martijn J. W. E. Rabelink,Leif Lindholm,Rob C. Hoeben	27
19	The p38 Mitogen-Activated Protein Kinase Inhibitor SB203580 Reduces Glucose Turnover by the Glucose Transporter-4 of 3T3-L1 Adipocytes in the Insulin-Stimulated State 2005 ·Endocrinology ·Merlijn Bazuine,Françoise Carlotti,Martijn J. W. E. Rabelink,Jort Vellinga,Rob C. Hoeben,J. Antonie Maassen	23
20	The Coiled-Coil Domain of the Adenovirus Type 5 Protein IX Is Dispensable for Capsid Incorporation and Thermostability 2005 ·Journal of Virology ·Jort Vellinga,Diana J.M. van den Wollenberg,(unknown),Martijn J. W. E. Rabelink,Rob C. Hoeben	38

About Jort Vellinga

Jort Vellinga is a scholar working on Genetics, Oncology and Infectious Diseases, having authored 25 papers that have together received 813 indexed citations. Recurring topics across this work include Virus-based gene therapy research (21 papers), Viral Infectious Diseases and Gene Expression in Insects (10 papers) and CAR-T cell therapy research (8 papers). The work is most often cited by research in Infectious Diseases (331 citations), Genetics (492 citations) and Oncology (210 citations). Jort Vellinga has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Rob C. Hoeben, Martijn J. W. E. Rabelink, Taco G. Uil, Diana J.M. van den Wollenberg, Jerome Custers, Roland Zahn, Jeroen de Vrij, Steve J. Cramer, Jerome Custers and Hanneke Schuitemaker. Their work appears in journals such as Nucleic Acids Research, PLoS ONE and Journal of Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact